Jacqueline Suen Garcia, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 37 | 2024 | 3620 | 4.540 |
Why?
|
Myelodysplastic Syndromes | 13 | 2024 | 1399 | 2.350 |
Why?
|
Sulfonamides | 15 | 2024 | 1980 | 1.810 |
Why?
|
Azacitidine | 11 | 2024 | 336 | 1.620 |
Why?
|
fms-Like Tyrosine Kinase 3 | 4 | 2023 | 494 | 0.960 |
Why?
|
Antineoplastic Agents | 10 | 2024 | 13697 | 0.830 |
Why?
|
Hematopoietic Stem Cell Transplantation | 7 | 2024 | 5713 | 0.800 |
Why?
|
Graft vs Host Disease | 2 | 2024 | 3044 | 0.740 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2024 | 1558 | 0.720 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 11854 | 0.690 |
Why?
|
Mycoses | 1 | 2022 | 386 | 0.620 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2021 | 646 | 0.560 |
Why?
|
Staurosporine | 1 | 2017 | 241 | 0.540 |
Why?
|
Boron Compounds | 1 | 2015 | 196 | 0.450 |
Why?
|
Protein Kinase Inhibitors | 3 | 2023 | 5708 | 0.430 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2016 | 656 | 0.420 |
Why?
|
Apoptosis | 5 | 2024 | 9516 | 0.400 |
Why?
|
Mitochondria | 3 | 2020 | 3675 | 0.400 |
Why?
|
Glycine | 1 | 2015 | 672 | 0.400 |
Why?
|
Transplantation, Homologous | 4 | 2024 | 4834 | 0.380 |
Why?
|
Mutation | 11 | 2024 | 30228 | 0.360 |
Why?
|
Leukemia | 5 | 2024 | 1526 | 0.340 |
Why?
|
Cytarabine | 3 | 2020 | 697 | 0.340 |
Why?
|
Drug Discovery | 1 | 2017 | 1067 | 0.320 |
Why?
|
Patient Selection | 1 | 2020 | 4266 | 0.310 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2024 | 1409 | 0.270 |
Why?
|
Philadelphia Chromosome | 2 | 2024 | 119 | 0.270 |
Why?
|
Remission Induction | 5 | 2024 | 2407 | 0.270 |
Why?
|
Nuclear Proteins | 3 | 2024 | 5800 | 0.250 |
Why?
|
Myeloproliferative Disorders | 2 | 2021 | 613 | 0.240 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2024 | 5336 | 0.230 |
Why?
|
Humans | 54 | 2024 | 768393 | 0.230 |
Why?
|
Graft vs Leukemia Effect | 1 | 2024 | 121 | 0.220 |
Why?
|
Asparaginase | 1 | 2024 | 240 | 0.210 |
Why?
|
Drug Resistance, Multiple | 1 | 2024 | 255 | 0.210 |
Why?
|
Azetidines | 1 | 2024 | 143 | 0.210 |
Why?
|
Recurrence | 4 | 2024 | 8506 | 0.190 |
Why?
|
Neutropenia | 2 | 2024 | 893 | 0.190 |
Why?
|
Dancing | 1 | 2022 | 105 | 0.180 |
Why?
|
Busulfan | 1 | 2021 | 259 | 0.180 |
Why?
|
Thrombocythemia, Essential | 1 | 2021 | 114 | 0.180 |
Why?
|
Vidarabine | 1 | 2021 | 337 | 0.180 |
Why?
|
Polycythemia Vera | 1 | 2021 | 160 | 0.170 |
Why?
|
Pyrimidines | 3 | 2024 | 3048 | 0.170 |
Why?
|
Transplantation Conditioning | 2 | 2024 | 1600 | 0.170 |
Why?
|
Mitoxantrone | 1 | 2019 | 148 | 0.170 |
Why?
|
Hematology | 1 | 2023 | 244 | 0.170 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 384 | 0.160 |
Why?
|
DNA, Mitochondrial | 1 | 2024 | 871 | 0.160 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2024 | 731 | 0.160 |
Why?
|
Clinical Trials as Topic | 3 | 2021 | 8051 | 0.150 |
Why?
|
Etoposide | 1 | 2019 | 639 | 0.150 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2024 | 1614 | 0.150 |
Why?
|
Azepines | 1 | 2019 | 329 | 0.150 |
Why?
|
Cell Cycle Proteins | 3 | 2024 | 3458 | 0.140 |
Why?
|
Immunotherapy | 2 | 2023 | 4738 | 0.140 |
Why?
|
Antifungal Agents | 1 | 2022 | 759 | 0.140 |
Why?
|
Thiophenes | 1 | 2020 | 569 | 0.130 |
Why?
|
Recombinant Fusion Proteins | 1 | 2024 | 3731 | 0.120 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
Piperidines | 1 | 2024 | 1659 | 0.120 |
Why?
|
Bone Marrow | 2 | 2023 | 2929 | 0.120 |
Why?
|
Immunophenotyping | 2 | 2019 | 1866 | 0.120 |
Why?
|
Superoxides | 1 | 2015 | 389 | 0.120 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2019 | 1339 | 0.120 |
Why?
|
Adult | 15 | 2024 | 223640 | 0.110 |
Why?
|
Disease-Free Survival | 2 | 2022 | 6856 | 0.110 |
Why?
|
Molecular Targeted Therapy | 2 | 2023 | 2830 | 0.110 |
Why?
|
Immunotherapy, Adoptive | 1 | 2023 | 1508 | 0.110 |
Why?
|
Protein Transport | 2 | 2016 | 1958 | 0.110 |
Why?
|
Glutathione | 1 | 2015 | 585 | 0.110 |
Why?
|
Drug Interactions | 1 | 2017 | 1420 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1794 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2024 | 3617 | 0.100 |
Why?
|
Hematologic Neoplasms | 1 | 2024 | 1905 | 0.100 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2144 | 0.100 |
Why?
|
Ribosomes | 1 | 2015 | 499 | 0.100 |
Why?
|
Signal Transduction | 5 | 2023 | 23631 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2024 | 1881 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3666 | 0.090 |
Why?
|
Cytoplasm | 1 | 2015 | 1502 | 0.090 |
Why?
|
Aged | 13 | 2024 | 171562 | 0.090 |
Why?
|
Aged, 80 and over | 8 | 2024 | 59686 | 0.090 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2015 | 775 | 0.090 |
Why?
|
Survival Rate | 2 | 2024 | 12870 | 0.090 |
Why?
|
Treatment Outcome | 7 | 2024 | 65379 | 0.090 |
Why?
|
Middle Aged | 14 | 2024 | 223491 | 0.090 |
Why?
|
Hospitals | 1 | 2023 | 3906 | 0.080 |
Why?
|
Prognosis | 5 | 2024 | 30022 | 0.080 |
Why?
|
DNA Methylation | 1 | 2024 | 4421 | 0.080 |
Why?
|
Oxidation-Reduction | 1 | 2015 | 2225 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10377 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2537 | 0.080 |
Why?
|
Autophagy | 1 | 2016 | 1351 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9433 | 0.080 |
Why?
|
Janus Kinase 2 | 2 | 2021 | 560 | 0.070 |
Why?
|
RNA-Binding Proteins | 1 | 2016 | 1883 | 0.070 |
Why?
|
Reactive Oxygen Species | 1 | 2015 | 2146 | 0.070 |
Why?
|
Female | 16 | 2024 | 397089 | 0.070 |
Why?
|
Lymphoma | 1 | 2016 | 1907 | 0.070 |
Why?
|
Male | 14 | 2024 | 364902 | 0.070 |
Why?
|
Age Factors | 2 | 2020 | 18471 | 0.070 |
Why?
|
Cell Survival | 1 | 2015 | 5792 | 0.060 |
Why?
|
Flow Cytometry | 1 | 2015 | 5900 | 0.060 |
Why?
|
Phosphoproteins | 2 | 2024 | 2448 | 0.060 |
Why?
|
Granulocyte Precursor Cells | 1 | 2024 | 49 | 0.060 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 1 | 2024 | 36 | 0.060 |
Why?
|
Chondroitin Sulfate Proteoglycans | 1 | 2024 | 142 | 0.060 |
Why?
|
Acrylamides | 1 | 2024 | 260 | 0.050 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2024 | 249 | 0.050 |
Why?
|
Gene Expression | 1 | 2015 | 7598 | 0.050 |
Why?
|
Cell Line, Tumor | 2 | 2016 | 17135 | 0.050 |
Why?
|
Maximum Tolerated Dose | 1 | 2024 | 890 | 0.050 |
Why?
|
Proteins | 1 | 2016 | 6006 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 13503 | 0.050 |
Why?
|
Adolescent | 4 | 2024 | 89184 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2015 | 7599 | 0.050 |
Why?
|
Anthracyclines | 1 | 2023 | 286 | 0.050 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2023 | 355 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18362 | 0.040 |
Why?
|
Idarubicin | 1 | 2019 | 59 | 0.040 |
Why?
|
Leukopenia | 1 | 2020 | 212 | 0.040 |
Why?
|
Molecular Biology | 1 | 2023 | 573 | 0.040 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2024 | 687 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2024 | 620 | 0.040 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 677 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 417 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2023 | 81801 | 0.040 |
Why?
|
Young Adult | 4 | 2024 | 60049 | 0.040 |
Why?
|
RNA Splicing | 1 | 2024 | 903 | 0.040 |
Why?
|
Aniline Compounds | 1 | 2024 | 1094 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 2 | 2022 | 4526 | 0.040 |
Why?
|
Prospective Studies | 1 | 2023 | 54920 | 0.040 |
Why?
|
Animals | 5 | 2024 | 169337 | 0.040 |
Why?
|
Genotype | 2 | 2024 | 13042 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2023 | 954 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 1019 | 0.030 |
Why?
|
Indoles | 1 | 2024 | 1825 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2024 | 39407 | 0.030 |
Why?
|
BH3 Interacting Domain Death Agonist Protein | 1 | 2015 | 88 | 0.030 |
Why?
|
Incidence | 2 | 2024 | 21544 | 0.030 |
Why?
|
Tissue Donors | 1 | 2024 | 2389 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 354 | 0.030 |
Why?
|
DNA Repair | 1 | 2024 | 2048 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 9510 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 230 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2021 | 2414 | 0.030 |
Why?
|
Neoplasms | 2 | 2021 | 22385 | 0.030 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 308 | 0.030 |
Why?
|
Retreatment | 1 | 2015 | 600 | 0.030 |
Why?
|
DNA Damage | 1 | 2024 | 2458 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 362 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 716 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2024 | 2952 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3212 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2533 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2020 | 1180 | 0.030 |
Why?
|
Phenotype | 2 | 2024 | 16721 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2017 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1839 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2397 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2022 | 2986 | 0.020 |
Why?
|
Transcription Factors | 2 | 2024 | 12166 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3941 | 0.020 |
Why?
|
Thalidomide | 1 | 2015 | 886 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2016 | 10478 | 0.020 |
Why?
|
Chromatin | 1 | 2022 | 2968 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6541 | 0.020 |
Why?
|
Mice | 3 | 2024 | 82017 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5619 | 0.020 |
Why?
|
Pneumonia | 1 | 2020 | 2163 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2021 | 3407 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2022 | 3827 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2020 | 5151 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2024 | 9614 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2574 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12456 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1881 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10267 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2846 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2552 | 0.020 |
Why?
|
Risk Factors | 2 | 2024 | 74962 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3610 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3107 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2021 | 11668 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6210 | 0.010 |
Why?
|
Child | 1 | 2021 | 80891 | 0.010 |
Why?
|